Post Tagged with: "epidiolex"

GW Pharmaceuticals Up on Encouraging Schizophrenia Data

GW Pharmaceuticals Up on Encouraging Schizophrenia Data

GW Pharmaceuticals plc GWPH was up 7.6% after the company announced encouraging top-line data from an exploratory phase IIa study on cannabidiol in patients suffering from schizophrenia who had previously failed to respond adequately to first-line anti-psychotic medications. In the multi-center, double-blind, placebo-controlled, six-week, phase II study, patients remained on their anti-psychotic medication and were randomized to receive either cannabidiol […]

September 18, 2015 · 0 comments · Feature Article
By 2016, Big Marijuana Company Could Win FDA Approval

By 2016, Big Marijuana Company Could Win FDA Approval

GW Pharma appears poised to enter the United States cannabis market with its flagship drug product. The drug, called Epidiolex, previously received fast-track status from the FDA and is now in the final Phase 3 study for pediatric epilepsy disorders, according to the Huffington Post. Results are expected in the first quarter of next year. Epidiolex is expected to “breeze […]

August 27, 2015 · 0 comments · Feature Article
GW Appoints Senior Industry Executive to President, North America and Relocates CEO to the U.S.

GW Appoints Senior Industry Executive to President, North America and Relocates CEO to the U.S.

GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the Company has appointed Julian Gangolli as President, North America and is also relocating its Chief Executive Officer, Justin Gover, to the United States. Mr Gangolli, was, from […]

June 8, 2015 · 0 comments · Feature Article
GW Pharmaceuticals Raising Cash As Pipeline Of Cannabis-Based Drugs Grows

GW Pharmaceuticals Raising Cash As Pipeline Of Cannabis-Based Drugs Grows

GW Pharmaceuticals (NASDAQ: GWPH) is planning to issue 1.25 million American Depositary shares in a public offering in an effort to raise some fresh cash. The company hasn’t provided many details about the offering, but investors are speculating that the firm is looking to continue expanding its research and development regarding new cannabis-based drugs. Closer To Creating A New Drug […]

May 1, 2015 · 0 comments · Feature Article
GW Pharma’s Epidiolex Can Treat Epilepsy According To Jim Cramer

GW Pharma’s Epidiolex Can Treat Epilepsy According To Jim Cramer

The U.K.-based pharmaceutical company, GW Pharmaceuticals, has several cannabinoid treatments, one of which targets epilepsy in children and has been able to significantly reduce the number of seizures in its patients, TheStreet’s Jim Cramer, manager of the Action Alerts PLUS portfolio, said on CNBC’s “Stop Trading” segment. Shares of GW Pharmaceuticals (GWPH) are up 9% on Tuesday on results from […]

April 17, 2015 · 0 comments · Feature Article
Marijuana May Be The Ultimate Treatment, But Research And Development Still Limited

Marijuana May Be The Ultimate Treatment, But Research And Development Still Limited

So far, GW Pharma has had promising results from two drugs currently in clinical trials to help treat cancerous brain tumors and has seen a marked improvement in sufferers of two types of childhood epilepsy using the company’s drug Epidiolex. Effect On Alzheimer’s While few studies have been done regarding the effect of THC on Alzheimer’s, the Journal of Alzheimer’s […]

March 3, 2015 · 0 comments · Feature Article
Will GW Pharmaceuticals (GWPH) Miss this Earnings Season?

Will GW Pharmaceuticals (GWPH) Miss this Earnings Season?

GW Pharmaceuticals plc (GWPH) is set to report first-quarter fiscal 2015 results on Feb 4, before the market opens. Last quarter, the company posted a positive earnings surprise of 104.35%. Let’s see how things are shaping up for this announcement. Factors at Play This Quarter The company’s key growth driver, Sativex, approved outside the U.S. for the treatment of spasticity […]

February 3, 2015 · 0 comments · Feature Article
Boy In Georgia Among The First Recipient Of Medical Cannabis

Boy In Georgia Among The First Recipient Of Medical Cannabis

Preston Weaver, who lives in Augusta, Georgia, has Lennox-Gastaut syndrome which is a severe form of epilepsy. He experiences up to 100 seizures a day, although many are confined to his brain and aren’t noticeable to an observer. There is no known cure for the condition. He is one of the many who first received medical pot as cure for […]

January 27, 2015 · 0 comments · Feature Article
Immunity Not Sufficient Enough For Medical Cannabis

Immunity Not Sufficient Enough For Medical Cannabis

About 40 families of children with seizures and other severe illnesses gathered to express their support, including Valerie Weaver of Augusta and her son, Preston, who is the first to get access to a marijuana oil drug called Epidiolex through a clinical trial at Georgia Regents University. Weaver said she will continue to come to Atlanta to lobby for the […]

January 14, 2015 · 0 comments · Feature Article
Marijuana Could Help People Suffering From These Diseases

Marijuana Could Help People Suffering From These Diseases

The first part of a phase 2/3 Dravet syndrome trial to determine the best dose was scheduled to conclude last month, and GW Pharmaceuticals expects to start the phase 3 portion of the trial and a second phase 3 trial in Dravet syndrome this quarter. There are also plans to start two additional phase 3 trials in Lennox-Gastaut syndrome patients […]

January 13, 2015 · 0 comments · Feature Article